US2011246399A1PendingUtilityA1
Predicting response to a her inhibitor
Est. expiryMar 2, 2027(~0.6 yrs left)· nominal 20-yr term from priority
A61P 35/00A61P 43/00A61P 15/00G01N 33/57557G01N 33/57555G01N 33/57545G01N 33/57515G01N 33/5752C12Q 2600/106A61K 45/06A61K 39/39558C12Q 1/6886G06Q 99/00C12Q 2600/118C12Q 2600/158A61K 31/7068B65B 61/20A61K 31/337A61K 2300/00
54
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. It also describes the use of high HER2:HER3 ratio as a selection criterion for treating cancer patients, such as ovarian cancer patients, with a HER inhibitor, such as pertuzumab. In addition, the application describes the use of high HER3 as a selection criterion for treating cancer patients with a chemotherapeutic agent, for instance gemcitabine.
Claims
exact text as granted — not AI-modified1 . A method for advertising a HER dimerization inhibitor or a pharmaceutically acceptable composition thereof comprising promoting, to a target audience, the use of the HER dimerization inhibitor or pharmaceutical composition thereof for treating a patient population with a type of cancer, where the patient's cancer expresses HER3 at a level less than the median level for HER3 expression in the cancer type.
2 . A method for advertising a HER inhibitor or a pharmaceutically acceptable composition thereof comprising promoting, to a target audience, the use of the HER inhibitor or pharmaceutical composition thereof for treating a patient population with a type of cancer, where the patient's cancer expresses HER2:HER3 at a level which is greater than the 25 th percentile for HER2:HER3 expression in the cancer type.Join the waitlist — get patent alerts
Track US2011246399A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.